The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Taking a technology company public is a milestone that brings both opportunity and complexity. While the spotlight often shines on the IPO day, it’s the careful orchestration behind the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results